研究者業績

藤原 慎一郎

フジワラ シンイチロウ  (Shinichiro Fujiwara)

基本情報

所属
自治医科大学 輸血・細胞移植部 教授

J-GLOBAL ID
201401051157883889
researchmap会員ID
B000237458

外部リンク

論文

 173
  • Hirofumi Nakano, Kazuya Sato, Hiroko Hayakawa, Kiyomi Mashima, Daisuke Minakata, Kaoru Morita, Ryoko Yamasaki, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Shin-ichiro Fujiwara, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
    Blood 132(Supplement 1) 3320-3320 2018年11月29日  
    <title>Abstract</title> Background Following activation by recognition of foreign antigens, human T-cells alter their metabolic pathways to meet the increasing energetic demands for efficient immune response. Like cancer cells, alloreactive T-cells show a preference for aerobic glycolysis rather than oxidative phosphorylation, which is referred to as "Warburg effect". Until recently, it has been thought that extracellular fatty acid (FA) uptake and β-oxidation are severely reduced in alloreactive T-cells; however, some studies have indicated that lipid metabolism is rather increased in alloreactive mouse T-cells, and that metabolic pathway of FA can be a promising target for GVHD. To determine the role of lipid metabolism in human alloreactive T-cells after hematopoietic stem cell transplantation, we investigated the metabolic changes in human T-cells in vivo using human-into-mouse xenogeneic GVHD models. Methods NOG mice received 250cGy of total body irradiation (TBI) and were subsequently injected intravenously with human pan T-cells. All mice developed severe GVHD and died within 2 weeks, while mice that received TBI only survived without any symptoms of GVHD. Cells were harvested from GVHD target organs of mice at day 9 after transplantation. For the measurement of glucose and fatty acid (FA) uptake by flow cytometry, cells were stained with fluorescent-labeled deoxyglucose analogue (2-NBDG) and long-chain fatty acid analogue (BODIPY 500/510 C12), respectively. PCR array and extracellular flux analysis were performed according to manufacturer's instructions. Results Glucose uptake, determined by flow cytometry, was significantly increased in human T-cells obtained from GVHD mice. Extracellular FA uptake was also increased in human T-cells in GVHD mice, and was associated with cell proliferation rate. Effector memory T-cells followed by central memory T-cells showed a higher FA uptake than did naive T-cells. These findings were similarly observed in both human CD4+ and CD8+ T-cells. Robust T-cell proliferation was observed even in MHC class I/II deficient (MHC−/−) NOG mice after transplantation, although to a lesser extent than MHC+/+ NOG mice, in a process known as homeostatic proliferation. Extracellular uptake of FA as well as glucose in T-cells was significantly decreased in MHC−/− NOG mice. Of note, even when compared among only fully proliferated T-cells between MHC+/+ and MHC−/− NOG mice, FA uptake was still significantly decreased in MHC−/− NOG mice, suggesting that the recognition of host MHC molecules by allogeneic T-cells accelerate this process. To compare the ability of human naive and memory T-cells to incorporate extracellular FA, we isolated human naive (CD45RA high) and memory (CD45RA low) T-cells and separately injected into NOG mice. Although it has been shown that memory T-cells exhibit different effector functions, the FA uptake in memory T-cells was comparable to that in naive T-cells. This suggests that memory T-cells can also alter their lipid metabolism following encounter with alloantigens. Finally, we assessed the expression of genes associated with lipid metabolism in human T-cells obtained from GVHD mice. Quantitative real-time PCR analysis detected up-regulation of mRNAs encoding the enzymes involved in FA transport including carnitine palmitoyltransferase (CPT1B), fatty acid binding protein (FABP1-4, FABP6, and FABP7), and β-oxidation pathway including acyl-CoA synthase (ACSBG2) and acyl-CoA dehydrogenase (ACAD9-11, ACADS, and ACADL) when compared with T-cells in MHC−/− NOG mice. Similarly, the expression of genes encoding the enzymes in triacylglycerol metabolism such as glycerol kinase (GK, GK2) and lipoprotein lipase (LPL) was up-regulated in GVHD mice. Furthermore, the expression of genes associated with mevalonate pathways such as HMG-CoA synthase (HMGCS1, HMGCS2), was also upregulated. These observations suggest that T-cells activated by alloantigens in vivo promote lipid hydrolysis, mitochondrial FA transport, and β-oxidation, resulting in greater utilization of free FA. Conclusion Human alloreactive T-cells increased extracellular uptake of FA as well as glucose, and intracellular lipid metabolism in response to alloantigens (summarized in the graphical abstract). Therapeutic effects of specific inhibition of lipid metabolic pathways by pharmacological inhibitors including etomoxir are now being investigated in this model. Figure. Figure. <sec> <title>Disclosures</title> Fujiwara: Shire: Consultancy; Pfizer: Consultancy; Chugai: Consultancy; Kirin: Consultancy; Kyowa-Hakko: Consultancy; Astellas: Consultancy. Ohmine:Kyowa Hakko Kirin: Speakers Bureau; Takara Bio: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda Pharmaceutical: Speakers Bureau; Celgene Corporation: Speakers Bureau; Chugai Pharmaceutical: Speakers Bureau; Alexion Pharmaceuticals: Speakers Bureau; Ono Pharmaceutical: Consultancy. Muroi:Japanese Red Cross Society: Speakers Bureau; Dickinson and Company: Speakers Bureau; Becton: Speakers Bureau; JCR: Speakers Bureau. Kanda:Astellas: Consultancy, Honoraria, Research Funding; Eisai: Consultancy, Honoraria, Research Funding; Taiho: Research Funding; Nippon-Shinyaku: Research Funding; Chugai: Consultancy, Honoraria, Research Funding; Dainippon-Sumitomo: Consultancy, Honoraria, Research Funding; Pfizer: Research Funding; Otsuka: Research Funding; Shionogi: Consultancy, Honoraria, Research Funding; Kyowa-Hakko Kirin: Consultancy, Honoraria, Research Funding; MSD: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Asahi-Kasei: Research Funding; Ono: Consultancy, Honoraria, Research Funding; Sanofi: Research Funding; Novartis: Research Funding; Taisho-Toyama: Research Funding; CSL Behring: Research Funding; Tanabe-Mitsubishi: Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria; Celgene: Consultancy, Honoraria; Mochida: Consultancy, Honoraria; Alexion: Consultancy, Honoraria; Takara-bio: Consultancy, Honoraria. </sec>
  • Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara S, Muroi K, Mori T, Kasama K, Iseki T, Nagamura-Inoue T, Fujii N, Ashida T, Kameda K, Kanda J, Hirose A, Takahashi T, Nagai K, Minakawa K, Tanosaki R
    BLOOD 132 2105 2018年11月  査読有り
  • Shoko Ito, Masahiro Ashizawa, Ryo Sasaki, Takashi Ikeda, Yumiko Toda, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Shin-Ichiro Fujiwara, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Jun Suzuki, Shuji Hatakeyama, Yuji Morisawa, Toshiyuki Yamada, Yoshinobu Kanda
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 24(10) 812-814 2018年10月  査読有り
    The 1,3-beta-D-Glucan (BDG) assay is widely used for the diagnosis of fungal infections, especially in patients with hematologic malignancies. Some antimicrobials have been reported to cause false-positive results for BDG, but there has been no report on the effect of penicillin G (PCG) on BDG levels. We experienced a patient who developed false-positive BDG elevation during the administration of PCG for osteomyelitis due to Streptococcus pneumoniae infection. The serum BDG level increased up to 81.0 pg/ml during the continuous administration of PCG at 24 million units per day. However, chest and paranasal CT scan showed no evidence of fungal infection. The BDG level decreased to 38.0 pg/ml at 14 hours after the discontinuation of PCG. The amount of BDG in one vial of PCG inferred from these serum BDG levels is very similar to the actual BDG concentration in a vial of PCG. Therefore, during the administration of PCG, elevated BDG levels should be interpreted with caution, as they may be false-positive results.
  • 皆方 大佑, 藤原 慎一郎, 早川 仁, 仲宗根 秀樹, 白土 裕也, 池田 喬司, 川口 慎一郎, 戸田 由美子, 伊藤 祥子, 越智 真一, 永山 隆史, 真島 清実, 海野 健斗, 中野 裕史, 山崎 諒子, 森田 薫, 川崎 泰史, 杉本 美幸, 山本 千裕, 蘆澤 正弘, 畑野 かおる, 佐藤 一也, 翁 家国, 大嶺 謙, 室井 一男, 大森 司, 神田 善伸
    臨床血液 59(9) 1582-1582 2018年9月  
  • Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y
    Hematology (Amsterdam, Netherlands) 23(8) 470-477 2018年9月  査読有り
  • 森田 薫, 木村 俊一, 齋藤 桐子, 早川 仁, 赤星 佑, 亀田 和明, 山本 千裕, 藤原 慎一郎, 越智 真一, 鈴木 貴之, 山田 茂樹, 田中 亨, 大城 久, 宮崎 義継, 澁谷 和俊, 神田 善伸
    Medical Mycology Journal 59(Suppl.1) 84-84 2018年8月  
  • Kawasaki Y, Sato K, Hayakawa H, Takayama N, Nakano H, Ito R, Mashima K, Oh I, Minakata D, Yamasaki R, Morita K, Ashizawa M, Yamamoto C, Hatano K, Fujiwara SI, Ohmine K, Muroi K, Kanda Y
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24(8) 1563-1574 2018年8月  査読有り
  • Kenji Motohashi, Shin Fujisawa, Noriko Doki, Takeshi Kobayashi, Takehiko Mori, Kensuke Usuki, Masatsugu Tanaka, Shinichiro Fujiwara, Shinichi Kako, Yasuyuki Aoyama, Masahiro Onoda, Shingo Yano, Moritaka Gotoh, Heiwa Kanamori, Satoshi Takahashi, Shinichiro Okamoto
    Leukemia & lymphoma 59(6) 1332-1337 2018年6月  査読有り
    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.
  • Ikeda K, Ohto H, Okuyama Y, Yamada-Fujiwara M, Kanamori H, Fujiwara SI, Muroi K, Mori T, Kasama K, Iseki T, Nagamura-Inoue T, Fujii N, Ashida T, Kameda K, Kanda J, Hirose A, Takahashi T, Nagai K, Minakawa K, Tanosaki R
    Transfusion medicine reviews 2018年6月  査読有り
  • Shin-ichiro Fujiwara, Yuya Shirato, Takashi Ikeda, Shin-ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shin-ichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Kaoru Morita, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
    International Journal of Hematology 107(6) 712-715 2018年6月1日  査読有り
  • Ishiyama Y, Fujiwara S, Fujishima N, Ito M, Sugimoto T, Saito S, Sakaguchi T, Nagai K, Masuoka H, Nagai K, Morita A, Kino S, Tanaka A, Hasegawa Y, Yokohama A, Fujino K, Shigeyoshi M, Matsumoto M, Takeshita A, Muroi K
    Vox Sanguinis 113 256 2018年4月  査読有り
  • Daisuke Minakata, Kazuya Sato, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Iekuni Oh, Shin-Ichiro Fujiwara, Ken Ohmine, Hirotoshi Kawata, Kazuo Muroi, Ikuo Miura, Yoshinobu Kanda
    Cancer genetics 220 44-48 2018年1月  
    Double-hit lymphoma (DHL) is defined as lymphoma with concurrent BCL2 and MYC translocations. While the most common histological subtype of DHL is diffuse large B-cell lymphoma, the present patient had leukemic follicular lymphoma (FL). A 52-year-old man was admitted to our hospital due to general fatigue and cervical and inguinal lymph node swelling. The patient was leukemic and the pathological diagnosis of the inguinal lymph node was FL grade 1. Chromosomal analysis revealed a complex karyotype including a rare three-way translocation t(8;14;18)(q24;q32;q21) involving the BCL2, MYC, and IGH genes. Based on a combination of fluorescence in situ hybridization (FISH), using BCL2, MYC and IGH, and spectral karyotyping (SKY), the karyotype was interpreted as being the result of a multistep mechanism in which the precursor B-cell gained t(14;18) in the bone marrow and acquired a translocation between der(14)t(14;18) and chromosome 8 in the germinal center, resulting in t(8;14;18). The pathological diagnosis was consistently FL, not only at presentation but even after a second relapse. The patient responded well to standard chemotherapies but relapsed after a short remission. This patient is a unique case of leukemic DH-FL with t(8;14;18) that remained in FL even at a second relapse.
  • 松本, 真弓, 長谷川, 雄一, 藤野, 惠三, 牧野, 茂義, 紀野, 修一, 竹下, 明裕, 池田, 和眞, 室井, 一男, 西岡, 純子, 奥山, 美樹, 中川, 美子, 河野, 武弘, 藤原, 慎一郎, 池田, 和彦, 横濱, 章彦, 田中, 朝志
    日本輸血細胞治療学会誌 64(4) 614-618 2018年  査読有り
    アフェレーシスナース58名を対象に、郵送によるアンケート調査を行い、40名(回収率69%)のデータを分析した。その結果、アフェレーシスナースの認定者同士のネットワークや交流について、11名(28%)が「日本輸血・細胞治療学会の総会や県内看護師会の中で有り」と回答した。末梢血幹細胞採取(採取)に関する知識習得のために活用しているものは、「学会誌」や「文献」で、4名(10%)が知識習得をしていなかった。37名(93%)が「認定取得後も採取に関連するトレーニングが必要」と回答し、主なトレーニングは「採血機器のトラブルシューティング」であった。アフェレーシスナースの活動成果は、「患者やドナーへの教育・指導」や「採取マニュアルの作成・整備」が多かった。活動への推進力は、「医師の理解・評価」や「患者・ドナーの評価」が多かった。26名(65%)が「認定資格を取得して良かった」と回答し、理由は「知識が向上した」が多かった。
  • Shinichi Kako, Shinichiro Fujiwara, Miki Sato, Shun-ichi Kimura, Hideki Nakasone, Kazuteru Ohashi, Toshiro Kawakita, Tetsuo Maeda, Takanobu Morishita, Ritsuro Suzuki, Takahiro Fukuda, Tatsuo Ichinohe, Mio Kurata, Yoshiko Atsuta, Yoshinobu Kanda
    Biology of Blood and Marrow Transplantation 24(10) 2139-2144 2018年  査読有り
  • Shin-ichiro Fujiwara, Shuichi Kino, Asashi Tanaka, Yuichi Hasegawa, Akihiko Yokohama, Keizo Fujino, Makino Shigeyoshi, Mayumi Matsumoto, Akihiro Takeshita, Kazuo Muroi
    TRANSFUSION AND APHERESIS SCIENCE 56(5) 708-712 2017年10月  査読有り
  • Hirofumi Nakano, Shin-ichiro Fujiwara, Shoko Ito, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    HEMATOLOGICAL ONCOLOGY 35(3) 357-364 2017年9月  査読有り
  • Daisuke Minakata, Shin-ichiro Fujiwara, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Ryoko Yamasaki, Kaoru Morita, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
    INTERNATIONAL JOURNAL OF HEMATOLOGY 106(3) 411-417 2017年9月  査読有り
  • Shoko Ito, Shin-ichiro Fujiwara, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Chihiro Yamamoto, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    ANNALS OF HEMATOLOGY 96(5) 719-724 2017年5月  査読有り
  • Kento Umino, Shin-Ichiro Fujiwara, Shoko Ito, Kiyomi Mashima, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Masahiro Ashizawa, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    LEUKEMIA & LYMPHOMA 58(2) 316-323 2017年2月  査読有り
  • Shin-ichiro Fujiwara, Kazuo Muroi, Chihiro Yamamoto, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Keiya Ozawa
    HEMATOLOGY 22(6) 347-353 2017年  査読有り
  • Kento Umino, Shin-ichiro Fujiwara, Kazuya Sato, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Kaoru Hatano, Kiyoshi Okazuka, Lekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    ACTA HAEMATOLOGICA 137(2) 93-99 2017年  査読有り
  • Kento Umino, Shin-ichiro Fujiwara, Takashi Ikeda, Yumiko Toda, Shoko Ito, Kiyomi Mashima, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Kazuo Muroi, Yoshinobu Kanda
    HEMATOLOGY 22(9) 521-526 2017年  査読有り
  • Chihiro Yamamoto, Shoko Ito, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Ryoko Yamasaki, Yasufumi Kawasaki, Miyuki Sugimoto, Hirofumi Nakano, Masahiro Ashizawa, Kiyoshi Okazuka, Kaoru Hatano, Kazuya Sato, Lekuni Oh, Shin-Ichiro Fujiwara, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    LEUKEMIA & LYMPHOMA 57(11) 2541-2547 2016年11月  査読有り
  • Kazuhiko Ikeda, Keiji Minakawa, Kazuo Muroi, Shin-ichiro Fujiwara, Minami Yamada-Fujiwara, Yoshihiro Fujimori, Ryuji Tanosaki, Hitoshi Ohto
    TRANSFUSION 56(11) 2839-2847 2016年11月  査読有り
  • Takahiro Suzuki, Hiroyuki Kobayashi, Yasufumi Kawasaki, Kiyoshi Okazuka, Kaoru Hatano, Shin-ichiro Fujiwara, Iekuni Oh, Ken Ohmine, Yoshinobu Kanda
    INTERNATIONAL JOURNAL OF HEMATOLOGY 104(4) 446-453 2016年10月  査読有り
  • Yoshinobu Maeda, Hisakazu Nishimori, Yoshihiro Inamoto, Hirohisa Nakamae, Masashi Sawa, Yasuo Mori, Kazuteru Ohashi, Shin-Ichiro Fujiwara, Mitsune Tanimoto
    ACTA MEDICA OKAYAMA 70(5) 409-412 2016年10月  査読有り
  • Miyuki Sugimoto, Shoko Ito, Kiyomi Mashima, Kento Umino, Daisuke Minakata, Hirofumi Nakano, Ryoko Yamasaki, Yasufumi Kawasaki, Masahiro Ashizawa, Chihiro Yamamoto, Shin-ichiro Fujiwara, Kiyoshi Okazuka, Kaoru Hatano, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Shinichi Kako, Yoshinobu Kanda
    ANNALS OF HEMATOLOGY 95(9) 1513-1519 2016年9月  査読有り
  • Daisuke Minakata, Shin-ichiro Fujiwara, Shoko Ito, Kiyomi Mashima, Kento Umino, Hirofumi Nakano, Yasufumi Kawasaki, Miyuki Sugimoto, Ryoko Yamasaki, Chihiro Yamamoto, Masahiro Ashizawa, Kaoru Hatano, Kiyoshi Okazuka, Kazuya Sato, Iekuni Oh, Ken Ohmine, Takahiro Suzuki, Kazuo Muroi, Yoshinobu Kanda
    LEUKEMIA RESEARCH 42 82-87 2016年3月  査読有り
  • Haruna Kogawara, Mato Naoko, Yamauchi Hiroyoshi, Sawata Testuro, Sata Masashi, Nakayama Masayuki, Nakaya Takakiyo, Fujiwara Shinichiro, Yamasawa Hideaki, Bando Masashi, Fukushima Noriyoshi, Sugiyama Yukihiko
    RESPIROLOGY 20 24 2015年12月  査読有り
  • 皆方 大佑, 室井 一男, 山本 千裕, 藤原 慎一郎, 神田 善伸
    日本輸血細胞治療学会誌 61(4) 461-462 2015年  
  • 藤原 慎一郎, 森 政樹, 室井 一男
    日本輸血細胞治療学会誌 61(1) 1-2 2015年  
  • Kaoru Hatano, Tadashi Nagai, Tomohiro Matsuyama, Yu Sakaguchi, Shin-ichiro Fujiwara, Iekuni Oh, Kazuo Muroi, Keiya Ozawa
    ACTA HAEMATOLOGICA 133(1) 98-100 2015年  査読有り
  • Takahiro Suzuki, Iekuni Oh, Ken Ohmine, Akiko Meguro, Masaki Mori, Shin-ichiro Fujiwara, Chihiro Yamamoto, Tadashi Nagai, Keiya Ozawa
    INTERNATIONAL JOURNAL OF HEMATOLOGY 101(1) 32-36 2015年1月  査読有り
  • Shin-ichiro Fujiwara, Kazuo Muroi, Raine Tatara, Tomohiro Matsuyama, Ken Ohmine, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Akira Tanaka, Keiya Ozawa
    LEUKEMIA & LYMPHOMA 55(2) 307-313 2014年2月  査読有り
  • Raine Tatara, Makoto Sato, Shin-ichiro Fujiwara, Iekuni Oh, Kazuo Muroi, Keiya Ozawa, Tadashi Nagai
    INTERNAL MEDICINE 53(20) 2365-2368 2014年  査読有り
  • Muroi K, Fujiwara S, Tatara R, Sato K, Oh I, Ohmine K, Suzuki T, Nagai T, Ozawa K, Kanda Y
    Journal of clinical and experimental hematopathology : JCEH 54(3) 243-245 2014年  査読有り
  • Fujiwara S, Muroi K, Tatara R, Ohmine K, Matsuyama T, Mori M, Nagai T, Ozawa K
    Case reports in hematology 2014 272458-272458 2014年  査読有り
  • Kazutaka Fukumura, Yoshihiro Yamashita, Masahito Kawazu, Eirin Sai, Shin-Ichiro Fujiwara, Naoya Nakamura, Kengo Takeuchi, Mizuo Ando, Kohei Miyazono, Toshihide Ueno, Keiya Ozawa, Hiroyuki Mano
    Oncology Reports 30(4) 1542-1548 2013年10月  査読有り
  • Shin-ichiro Fujiwara, Kazuo Muroi, Yuji Hirata, Kazuya Sato, Tomohiro Matsuyama, Ken Ohmine, Takahiro Suzuki, Katsutoshi Ozaki, Masaki Mori, Tadashi Nagai, Akira Tanaka, Keiya Ozawa
    HEMATOLOGY 18(1) 14-19 2013年1月  査読有り
  • Raine Tatara, Tadashi Nagai, Mizuho Suzuki, Iekuni Oh, Shin-ichiro Fujiwara, Masataro Norizuki, Kazuo Muroi, Keiya Ozawa
    INTERNAL MEDICINE 52(17) 1987-1990 2013年  査読有り
  • Muroi K, Fujiwara S, Tatara R, Sugimoto M, Yamamoto C, Uehara E, Meguro A, Hatano K, Okazuka K, Oh I, Ohmine K, Suzuki T, Mori M, Nagai T, Ozawa K
    Journal of clinical and experimental hematopathology : JCEH 53(3) 247-250 2013年  査読有り
  • Hosonuma R, Fujiwara S, Sasazaki M, Hirata Y, Yamamoto C, Uesawa M, Oh I, Matsuyama T, Mori M, Ozawa K, Muroi K
    [Rinsho ketsueki] The Japanese journal of clinical hematology 53(4) 469-471 2012年4月  査読有り
  • Oka S, Muroi K, Fujiwara S, Oh I, Matsuyama T, Ohmine K, Suzuki T, Ozaki K, Mori M, Nagai T, Ozawa K, Hanafusa T
    Journal of clinical and experimental hematopathology : JCEH 52(1) 63-66 2012年  査読有り
  • Kobayashi H, Matsuyama T, Oka S, Fujiwara S, Oh I, Suzuki T, Ozaki K, Mori M, Nagai T, Ozawa K, Muroi K
    Journal of clinical and experimental hematopathology : JCEH 52(1) 81-83 2012年  査読有り
  • Oka S, Muroi K, Sato K, Fujiwara S, Oh I, Matsuyama T, Ohmine K, Suzuki T, Ozaki K, Mori M, Nagai T, Fukushima N, Fukushima N, Tanaka A, Ozawa K
    Journal of clinical and experimental hematopathology : JCEH 52(2) 127-131 2012年  査読有り
  • Akiko Meguro, Katsutoshi Ozaki, Kazuya Sato, Iekuni Oh, Shinichiro Fujiwara, Rie Hosonuma, Miyuki Sasazaki, Yuji Kikuchi, Yuji Hirata, Chihiro Yamamoto, Mitsuyo Uesawa, Hiroyuki Kobayashi, Haruko Matsu, Hiroshi Okabe, Eisuke Uehara, Akinori Nishikawa, Raine Tatara, Kaoru Hatano, Chizuru Yamamoto, Tomohiro Matsuyama, Masaki Toshima, Masuzu Ueda, Ken Ohmine, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa
    LEUKEMIA & LYMPHOMA 53(1) 43-49 2012年1月  査読有り
  • Yuasa M, Fujiwara S, Oh I, Yamaguchi T, Fukushima N, Morimoto A, Ozawa K
    Journal of clinical and experimental hematopathology : JCEH 52(2) 121-126 2012年  査読有り
    Langerhans cell histiocytosis (LCH) is a clonal neoplasm that shows diverse clinical manifestations and courses of disease progression. The etiology and pathophysiology of LCH remain uncertain. We describe the clinical course of a 23-year-old Japanese woman with multi-system LCH, who showed rapid progression after steroid reduction and developed multi-organ failure. Liver biopsy showed LCH infiltration with fatty degeneration. She was treated with cytarabine, vincristine, and prednisolone according to the Japan LCH study group 02 protocol, without any clinical improvement. Low expression of Ki67 and bcl-2 failed to explain the rapid clinical course. Panhypopituitarism and hypothalamic dysfunction may have caused nonalcoholic fatty liver disease and liver failure. This case indicates that some multi-system LCH patients with hypopituitarism and hypothalamic dysfunction show very rapid progression and are difficult to treat. [J Clin Exp Hematopathol 52(2) : 121-126, 2012]
  • Yuji Hirata, Koji Kishino, Fumiko Onozaki, Yoko Nakaki, Shin-ichiro Fujiwara, Chizuru Yamamoto, Kazuya Sato, Tomohiro Matsuyama, Katsutoshi Ozaki, Masaki Mori, Keiya Ozawa, Kazuo Muroi
    HEMATOLOGY 16(4) 221-224 2011年7月  査読有り
  • Kazuya Sato, Katsutoshi Ozaki, Shin-ichiro Fujiwara, Iekuni Oh, Tomohiro Matsuyama, Ken Ohmine, Takahiro Suzuki, Masaki Mori, Tadashi Nagai, Kazuo Muroi, Keiya Ozawa
    INTERNATIONAL JOURNAL OF HEMATOLOGY 92(4) 647-650 2010年11月  査読有り
  • Tadashi Nagai, Ken Ohmine, Shin-ichiro Fujiwara, Mitsuyo Uesawa, Chihiro Sakurai, Keiya Ozawa
    LEUKEMIA RESEARCH 34(8) 1057-1063 2010年8月  査読有り

MISC

 56

講演・口頭発表等

 3

共同研究・競争的資金等の研究課題

 4